Renal Insufficiency, Acute
Conditions
Keywords
Biological Markers, Renal Replacement Therapy, Mortality
Brief summary
The purpose of this study is to find new blood and urine tests that detect acute kidney injury earlier than our current blood tests in patients receiving a liver transplant.
Detailed description
Patients with end stage liver disease that receive a liver transplant will be studied to determine if novel serum and urine biomarkers (serum cystatin C, urine interleukin-18 \[IL-18\] and urine neutrophil gelatinase associated lipocalin \[NGAL\]) can predict the outcome measures listed above.
Interventions
None listed
Sponsors
University of Washington
Denver Health Medical Center
Children's Hospital Medical Center, Cincinnati
University of Colorado, Denver
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* First time liver transplant recipient * Cadaveric or living donor livers
Exclusion criteria
* Unconscious patients or patients who cannot give consent * Pregnant women * Prisoners * Patients receiving dialysis before or during liver transplant operation * Patients receiving simultaneous liver-kidney transplants
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Development of acute kidney injury as defined by a 50% increase in serum creatinine | Within 2 to 5 days of liver transplant that is sustained for at least 24 hours |
Secondary
| Measure | Time frame |
|---|---|
| Development of severe acute kidney injury, as defined as a doubling of serum creatinine | Within 2-5 days of transplant that is sustained for at least 24 hours |
| The need for renal replacement therapy | After liver transplant operation to discharge |
| All cause mortality | After liver transplant operation to discharge |
Countries
United States
Outcome results
None listed